New Insights in Nanomedicine and Targeted Drugs for Breast Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Drug Development".
Deadline for manuscript submissions: 31 January 2026 | Viewed by 291
Special Issue Editors
Interests: genetics; molecular biology; proteomics; microbiome; cancer; inflammation; nanomedicine
Special Issues, Collections and Topics in MDPI journals
Interests: nanomedicine; nanoparticles for drugs delivery; CryoEM; biosensors
Interests: molecular biology; cancer; inflammation; nanomedicine
Interests: natural compounds for disease prevention; cancer; biochemistry; novel therapeutic compounds; inflammation
Special Issue Information
Dear Colleagues,
Breast cancer (BC) is one of the most common cancers in the world and is one of the deadliest diseases for women. The creation of specific drug delivery systems against BC has become one of the main objectives of nanomedicine in the last 20 years.
I am pleased to request your contribution to this Special Issue "New Insights in Nanomedicine and Targeted Drugs for Breast Cancer".
The topic will focus on anticancer nanoplatforms to BC cells loaded with drugs or contrast agents for BC in clinical and preclinical research. The focus will be on the production of nanosystems for active delivery in breast cancer cells in the tumor stroma and/or directly in BC cells, with particular attention to BC disease resistant to classical drugs and to innovative diagnostic.
In this Special Issue, original research articles and reviews are welcome.
Research areas may include, but are not limited to, nanomedicine for BC cells; EPR accumulation of drug to BC; BC-specific treatment with nanomedicine.
Dr. Maria Gazouli
Dr. Gennaro Sanità
Dr. Alessandro Venuta
Dr. Rosarita Nasso
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- breast cancer
- nanoparticles
- active targeting
- BC
- nanomedicine
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
